Literature DB >> 27824856

Amgen's migraine antibody advances.

.   

Abstract

Entities:  

Year:  2016        PMID： 27824856     DOI： 10.1038/nbt1116-1084a

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Migraine mAbs crowd into late-stage trials.

Authors:  Gunjan Sinha
Journal:  Nat Biotechnol       Date:  2015-07       Impact factor: 54.908
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.